Understanding breast cancer response during pre-surgery treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study collects breast cancer tissue and blood samples from patients undergoing neoadjuvant systemic therapy before surgery. It aims to investigate the molecular and genetic factors that influence treatment response and identify patients at higher risk of cancer recurrence. Additionally, MRI scans and stool samples may be obtained to enhance the understanding of treatment effects. The findings could lead to improved methods for measuring treatment response and tailoring therapies for better outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Histologically confirmed non-metastatic invasive breast cancer.
2. Be suitable for, but have not commenced, neoadjuvant chemotherapy, targeted therapy, or immunotherapy.
3. If HER2-, suitable for treatment with upfront taxane chemotherapy. If HER2+, suitable for treatment with anti-HER2 targeted therapy.
4. Be aged 18 years and over.
5. Have given written informed consent to participate.

Exclusion Criteria:

1. Metastatic breast cancer at diagnosis.
2. Treatment with neoadjuvant endocrine therapy only.
3. Presence of any psychological, familial or sociological condition potentially hampering compliance with the study protocol and follow-up schedule.

Where it's running

• Royal Marsden NHS Foundation Trust
  London, United Kingdom Recruiting

Study contacts

• Principal investigator: Stephen-John Sammut — Royal Marsden NHS Foundation Trust
• Study coordinator: BELIEVE Trial Manager
• Email: BELIEVE@rmh.nhs.uk
• Phone: 02078082887

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Evaluating PC14586 for advanced solid tumors with a specific mutation

  This study is testing a new oral medication called PC14586 to see if it can help people with advanced solid tumors that have a specific mutation in the TP53 gene.

  Recruiting at 71 sites Phase 1/2 PMV Pharmaceuticals, Inc · Irvine, California and 75 other locations · NCT04585750

• Adding targeted radiation therapy to drug treatment for breast cancer

  This study is testing whether adding targeted radiation therapy to regular drug treatment can help people with a specific type of breast cancer keep their disease from getting worse or spreading.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 7 other locations · NCT05534438

• Can older adults with breast cancer tolerate a dense CMF chemo schedule

  This study tests whether giving a condensed CMF chemotherapy regimen is feasible for people 70 and older with breast cancer.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07768436

• Pre-surgery hormone therapy to lower positive margins in lobular breast cancer

  This Phase 2 trial tests whether giving endocrine (hormone) therapy before breast-conserving surgery can reduce the chance of cancer at the edges of the removed tissue in postmenopausal people with ER+/HER2- invasive lobular breast cancer.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07483307

• Adherence to Cell Cycle Inhibitors with Endocrine Therapy in Localized High-Risk ER+ Breast Cancer

  This study checks how well patients with localized ER+ breast cancer stick to a combined endocrine therapy and CDK4/6 inhibitor after surgery.

  Recruiting University Hospital, Grenoble · Grenoble · NCT07443774

• Extended-interval versus standard-interval immunotherapy for advanced triple-negative breast cancer

  This trial tests whether giving immunotherapy less often works as well and causes fewer immune-related side effects than the standard schedule for adults with advanced triple-negative breast cancer who responded to initial combination therapy.

  Recruiting Phase 2 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT07401537

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.